#heateor_sss_mastodon_popup_bg,#heateor_sss_popup_bg{--wpr-bg-9b170f74-f044-495f-b4b6-265a96f3b718: url('https://www.delveinsight.com/blog/blog/wp-content/plugins/sassy-social-share/images/transparent_bg.png');}.rll-youtube-player .play{--wpr-bg-301fe896-1e8f-49fa-8dfb-5cee358eb174: url('https://www.delveinsight.com/blog/wp-content/plugins/wp-rocket/assets/img/youtube.png');}

0

Home Blog Tag Lung therapeutics

Lung Therapeutics

Jun 06, 2019

The Business Cocktail

Cancer biotech Inhibrx files for USD 75 M IPO Celgene-partnered biotech Inhibrx aftersecuring USD 40 Million from Viking Global Investors, has filed for USD 75 million IPO. Built on a single-domain antibody platform, it has three oncology programs in human clinical trials, a rare disease program, and two preclin...

Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies

Snippets - A Small piece of News or Article

Jul 04, 2025

A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray

Articles

Jun 10, 2025

ADCs in Lung Cancer Treatment: ENHERTU’s Rise, HER3 & TROP-2 Challenges, and What’s Next in the Pipeline

Articles

May 09, 2025

LEQEMBI: A New Hope for Alzheimer’s Disease Patients

Articles